Rapid Therapeutic Science Stock Debt To Equity
| RTSL Stock | USD 0 0.00 0.00% |
Rapid Therapeutic Science fundamentals help investors to digest information that contributes to Rapid Therapeutic's financial success or failures. It also enables traders to predict the movement of Rapid Pink Sheet. The fundamental analysis module provides a way to measure Rapid Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rapid Therapeutic pink sheet.
Rapid |
Rapid Therapeutic Science Company Debt To Equity Analysis
Rapid Therapeutic's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Rapid Therapeutic Debt To Equity | 1.13 % |
Most of Rapid Therapeutic's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rapid Therapeutic Science is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Rapid Therapeutic Science has a Debt To Equity of 1.13%. This is 97.89% lower than that of the Healthcare sector and 97.18% lower than that of the Medical Devices industry. The debt to equity for all United States stocks is 97.68% higher than that of the company.
Rapid Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rapid Therapeutic's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rapid Therapeutic could also be used in its relative valuation, which is a method of valuing Rapid Therapeutic by comparing valuation metrics of similar companies.Rapid Therapeutic is currently under evaluation in debt to equity category among its peers.
Rapid Fundamentals
| Return On Asset | -0.55 | |||
| Current Valuation | 13.08 M | |||
| Shares Outstanding | 7.75 M | |||
| Shares Owned By Insiders | 66.33 % | |||
| Price To Book | 136.70 X | |||
| Price To Sales | 193,667 X | |||
| Revenue | 534 | |||
| Gross Profit | 334 | |||
| EBITDA | (1.48 M) | |||
| Net Income | (2.87 M) | |||
| Cash And Equivalents | 112.16 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 150 K | |||
| Debt To Equity | 1.13 % | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0.40) X | |||
| Cash Flow From Operations | (2.21 M) | |||
| Earnings Per Share | (0.51) X | |||
| Beta | -10.77 | |||
| Market Capitalization | 4.22 M | |||
| Total Asset | 2.2 M | |||
| Z Score | 16.8 | |||
| Net Asset | 2.2 M |
About Rapid Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rapid Therapeutic Science's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rapid Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rapid Therapeutic Science based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.